Now Reading: 20 stocks in focus: Signature Global, IndusInd Bank, pharma
-
01
20 stocks in focus: Signature Global, IndusInd Bank, pharma
The Hindu Business Line reports Signature Global awarded Rs 920 crore in construction contracts to KEC International and NCC for 11 towers at its Dwarka Expressway project. Work starts in Q3 FY27.…
The Story in Brief
The Hindu Business Line reports Signature Global awarded Rs 920 crore in construction contracts to KEC International and NCC for 11 towers at its Dwarka Expressway project. Work starts in Q3 FY27. IndusInd Bank got RBI approval for a stockbroking subsidiary. In pharma, Novartis India ended its Dr Reddy's distribution pact, Emcure Pharma received a USFDA inspection closure (VAI classification), and AstraZeneca got CDSCO clearance for a breast cancer drug. Gland Pharma signed a sterile injectable manufacturing deal. RITES inked an HPCL MoU for railway siding consultancy. Neetu Yoshi starts production on September 13, 2026, and Fujiyama Power commissioned a 2 GW plant in Madhya Pradesh.
The Indian Opinion
The market often treats contract wins and regulatory nods as instant positives, but timelines and conditions matter. Signature Global's Rs 920 crore project begins in FY27, offering no near-term earnings boost. Emcure's VAI classification means the USFDA found minor issues, not a clean record. Investors should watch actual revenue from these deals and any follow-up regulatory actions before assuming all news is equally good.
Source: thehindubusinessline.com
This story was synthesised by AI from the source linked above.
